International Summit on Psychedelic Therapies for Mental Illness, Melbourne, Australia
November 16, 2020 - November 19, 2020
Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2020 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy makers, business, industry, and other interested stakeholders.
The event will also feature a two-day pre-summit workshop program for therapists and health professionals who are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the treatment of mental illness.
The summit will feature a rich program targeted specifically to medical, scientific, research, allied health, legal, philanthropic and Government leaders and emerging talent, with a mixture of international and national keynotes, master classes, hot spots, panel conversations and gala dinner.
Speakers line-up will feature international researchers and leaders, alongside Mind Medicine Australia Ambassadors including Head of Neuropsychopharmacology at Imperial College London Prof David Nutt (UK), Executive Director of MAPS Dr Rick Doblin (USA), psychiatrist, researcher and writer Dr Ben Sessa (UK), Head of the Centre for Psychedelic Research at Imperial College London Dr Robin Carhart-Harris (UK), James B. Duke Professor of Psychology and Behavioural Economics at Duke University, Prof Dan Ariely (USA/Israel), Clinical Lead of the Imperial College London Psilocybin for Depression study Dr Rosalind Watts (UK), Director Center for Psychedelic Therapies and Research at CIIS Professor Janis Phelps (USA) and Associate Professor of Psychiatry at Johns Hopkins University School of Medicine, A/Prof Matthew Johnson (USA).
Key themes will include:
- Ethical, legal, and implementation frameworks for psychedelic treatments
- The current state of mental health in Australia and existing treatments
- Clinical outcomes of psychedelic treatment for mental illness
- Therapeutic mechanisms of psychedelic treatments
- Enhancing effectiveness and minimising risks for psychedelic treatment
- The way forwards for Australia: Challenges and preparation towards creating a new paradigm
Psychedelic therapies have been granted Breakthrough Therapy status by the FDA in the USA due to current promising research in the treatment of depression and PTSD. We look forward to collaborating with you to explore psychedelic treatment options to help address the mental health crisis we currently face, and offer treatments to those who need it most.
We are delighted to extend an invitation to you and your colleagues to gather in Melbourne in November 2020.
Together we can change the paradigm for mental health.
For more details and to be notified when tickets go on sale, please subscribe at the bottom of this page.